Dr. Reddy's strikes back at AstraZeneca in purple pill courtroom battle

AstraZeneca ($AZN) has been duking it out with Dr. Reddy's Laboratories over generic Nexium, winning a round last week after a Delaware district judge put the kibosh on sales of Dr. Reddy's generics and said that Nexium's distinctive purple hue protected it from copycat competitors. But Dr. Reddy's isn't going down without a fight. The Hyderabad, India-based generics maker recently struck back in court, claiming AstraZeneca knew that Dr. Reddy's intended to use the color purple for its capsule but still went ahead with its lawsuit. Now Dr. Reddy's is seeking damages to recoup its losses, The Economic Times reports. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.